The present disclosure provides boron-containing diacylhydrazines having Formula I:
and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.
本公开提供具有I式的含
硼二酰
肼化合物及其药学上可接受的盐和溶剂化物,其中R1、R2、R3、R4和R5如规范所述。本公开还提供使用含
硼二酰
肼化合物的Ecdysone受体基于诱导
基因表达系统。因此,本公开对于
基因治疗、疾病治疗、大规模蛋白质和
抗体生产、基于细胞的筛选分析、功能
基因组学、蛋白质组学、代谢组学以及调控转
基因生物的性状等应用非常有用,其中对
基因表达
水平的控制是必要的。